The dosage of ropeginterferon in polycythaemia vera: Balancing efficacy, safety and pharmacoeconomics across risk categories.

Barbui T, Tefferi A, Vannucchi AM

Open source

DOI
10.1111/bjh.19996
Published
2025 Mar
Container
British journal of haematology
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1111/bjh.19996,
  title = {The dosage of ropeginterferon in polycythaemia vera: Balancing efficacy, safety and pharmacoeconomics across risk categories.},
  author = {Barbui T and Tefferi A and Vannucchi AM},
  year = {2025},
  journal = {British journal of haematology},
  doi = {10.1111/bjh.19996},
  url = {https://doi.org/10.1111/bjh.19996}
}

RIS

TY  - JOUR
TI  - The dosage of ropeginterferon in polycythaemia vera: Balancing efficacy, safety and pharmacoeconomics across risk categories.
AU  - Barbui T
AU  - Tefferi A
AU  - Vannucchi AM
PY  - 2025
JO  - British journal of haematology
DO  - 10.1111/bjh.19996
UR  - https://doi.org/10.1111/bjh.19996
ER  - 

APA

T, B., A, T., & AM, V. (2025). The dosage of ropeginterferon in polycythaemia vera: Balancing efficacy, safety and pharmacoeconomics across risk categories.. British journal of haematology. https://doi.org/10.1111/bjh.19996

Source records